tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Eli Lilly receives CHMP opinion recommending donanemab for Alzheimer’s

Eli Lilly (LLY) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has issued an opinion recommending donanemab for the treatment of early symptomatic Alzheimer’s disease in adults with confirmed amyloid pathology who are apolipoprotein E e4 heterozygotes or non-carriers. The European Commission is expected to make a regulatory decision on donanemab in the coming months.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1